Merck & Co., Inc: Neoplasms trials
The registry lists 89 Neoplasms studies with Merck & Co., Inc as lead sponsor. 15 are open to participants now and 33 have results posted.
Phase 1 69Phase 2 22Phase 3 3Phase 4 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)Not yet recruitingNCT07876128Phase 1/2
- A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)Not yet recruitingNCT07801027Phase 4
- A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)RecruitingNCT07785609Phase 2
- A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)RecruitingNCT07700758Phase 2
- A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)RecruitingNCT07630974Phase 1/2
- Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)RecruitingNCT07600749Phase 1
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3
- A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)RecruitingNCT07302347Phase 1/2
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)RecruitingNCT07252739Phase 2
- A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)RecruitingNCT07247110Phase 1
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)RecruitingNCT07209111Phase 2
- A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)RecruitingNCT07030712Phase 1
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)RecruitingNCT06979596Phase 2
- A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)RecruitingNCT06941272Phase 1/2
- A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)RecruitingNCT06818643Phase 1/2
- A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)TerminatedNCT03948763Phase 1Results posted
- Extended Administration of Polyethylene Glycol (PEG) Interferon Alfa-2b in Participants With Solid Tumors (C/I97-349/MK-4031-009)CompletedNCT03554005Phase 1Results posted
- A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)TerminatedNCT03520959Phase 3Results posted
- Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)TerminatedNCT03515824Phase 1Results posted
- Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)CompletedNCT03326986Phase 1Results posted
- Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)TerminatedNCT03099161Phase 1Results posted
- Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)TerminatedNCT02972034Phase 1Results posted
- Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)CompletedNCT02964013Phase 1Results posted
- Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)CompletedNCT02862457Phase 1Results posted
- Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)TerminatedNCT02761694Phase 1Results posted
- Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)TerminatedNCT02731742Phase 1Results posted
- Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)CompletedNCT02720068Phase 1Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)CompletedNCT01848834Phase 1Results posted
- A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)CompletedNCT01636947Phase 4Results posted
- Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)CompletedNCT01380184Phase 1Results posted
- A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)TerminatedNCT01358331Phase 1Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)CompletedNCT01295827Phase 1Results posted
- A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)TerminatedNCT01243762Phase 1Results posted
- A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)TerminatedNCT00960063Phase 1Results posted
- Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)TerminatedNCT00954512Phase 1/2Results posted
- Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)TerminatedNCT00931606Phase 2Results posted
- Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)CompletedNCT00880568Phase 1Results posted
- A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)CompletedNCT00848718Phase 1Results posted
- A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED)CompletedNCT00800865Phase 1Results posted
- A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)CompletedNCT00779584Phase 1Results posted
- Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)CompletedNCT00773747Phase 3Results posted
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)CompletedNCT00753415Phase 1Results posted
- Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)CompletedNCT00694356Phase 1Results posted
- Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)CompletedNCT00670488Phase 1Results posted
- Treatment of Participants With Advanced and/or Refractory Solid Tumors (MK-5108-001)CompletedNCT00543387Phase 1Results posted
- A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)TerminatedNCT00424775Phase 1Results posted
- A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)CompletedNCT00373490Phase 1Results posted
- A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)CompletedNCT00127127Phase 1Results posted
- A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1
- Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)CompletedNCT05514444Phase 1
- Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)Active, not recruitingNCT04976634Phase 2
- A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)CompletedNCT03918278Phase 1
- Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)CompletedNCT03564691Phase 1
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruitingNCT03162536Phase 1/2
- A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)TerminatedNCT02532868Phase 1
- Open-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleTerminatedNCT02476955Phase 1
- A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid TumorsStatus unknownNCT01724320Phase 1
- Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaCompletedNCT01473095Phase 1
- A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)TerminatedNCT01226901Phase 1
- Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid TumorsCompletedNCT00874042Phase 1
- Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid TumorsCompletedNCT00827177Phase 1
- Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic MalignanciesCompletedNCT00825487Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)CompletedNCT00750178Phase 1
- A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004)CompletedNCT00730379Phase 1
- Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)CompletedNCT00694083Phase 1
- Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)CompletedNCT00687011Phase 4
- Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)CompletedNCT00684463Phase 4
- A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)CompletedNCT00647114Phase 1
- An Extension Study for Patients Previously Treated With ARQ 501CompletedNCT00622063Phase 1/2
- A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612703Phase 1
- A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid TumorsCompletedNCT00612209Phase 1
- MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)CompletedNCT00496353Phase 1/2
- A Study of ARQ 171 in Patients With Advanced Solid TumorsTerminatedNCT00398840Phase 1
- Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With OpioidTerminatedNCT00331045Phase 2
- Safety and Efficacy Study of ARQ 501 in Adult Patients With LeiomyosarcomaCompletedNCT00310518Phase 2
- ARQ 197 in Subjects With Metastatic Solid TumorsCompletedNCT00302172Phase 1
- Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)CompletedNCT00288431Phase 1
- Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain SubjectsCompletedNCT00135577Phase 2
- AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)CompletedNCT00122343Phase 2
- Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)CompletedNCT00112372Phase 1
- Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)CompletedNCT00110188Phase 2
- A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)CompletedNCT00104364Phase 1
- ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic CancerCompletedNCT00102700Phase 2
- ARQ 501 in Combination With Docetaxel in Patients With CancerCompletedNCT00099190Phase 1
- ARQ 501 in Subjects With CancerCompletedNCT00075933Phase 1
- Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)CompletedNCT00060645Phase 1
- Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)CompletedNCT00060632Phase 1
- Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)CompletedNCT00040547Phase 1
- Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)TerminatedNCT00040534Phase 1